---
prompt_id: 04-koji-uricase-hypothesis-gen
prompt_sha256_12: 9dc91d95f2f9
vendor: openai
model_requested: openai/gpt-5.5
model_served: openai/gpt-5.5
model_served_raw: openai/gpt-5.5-20260423
call_timestamp_utc: 2026-05-14T15:32:09.651677Z
latency_seconds: 146.26
input_tokens: 334
output_tokens: 6410
cost_usd: 0.0779
finish_reason: stop
response_sha256_12: d19df580a6c1
status: ok
---

Assumptions:

- Work is limited to contained BSL-1 laboratory practice with a non-toxigenic food-grade *A. oryzae* strain; no *A. flavus* culture is required, only sequence information.
- Costs exclude personnel time and assume access to standard molecular biology infrastructure, a plate reader or spectrophotometer, and basic fungal culture capability.
- “amyB promoter” is treated as the proposed cassette promoter, but note that native *A. oryzae amyB* regulation is carbon-source responsive rather than truly constitutive.
- No ingestion, animal testing, human sampling, or environmental release is part of these Phase-0 experiments.

| Order | Experiment | Question answered | Cost | Timeline | Decision informed | Biggest risk to interpretability |
|---:|---|---|---|---|---|---|
| 1 | **In-silico secretory-expression liability audit of the α-amylaseSP–AfUox cassette** | Does the current coding and fusion design contain predictable liabilities for expression, secretion, folding, glycosylation, or extracellular activity in *A. oryzae*? | In silico, ~$0 | 1–3 days | Modify sequence before synthesis; change signal peptide/linker; recode problematic motifs; choose alternative uricase; or proceed to build | Prediction tools may not capture *A. oryzae*-specific secretion, folding, proteolysis, or glycosylation behavior |
| 2 | **Parental-strain amyB promoter state-mapping under intended production media** | Is the endogenous *amyB* regulatory program active under the planned carbon/nitrogen/process conditions, or is the cassette promoter likely to be repressed? | Low wet-lab, <$500 | Several days to ~2 weeks | Keep *amyB* promoter; alter production medium/induction regime; or switch to a different promoter before cassette construction | Endogenous *amyB* behavior may not predict the same promoter driving a heterologous cassette at a different genomic/episomal context |
| 3 | **Small-scale transient secretion-and-activity pilot of the exact α-amylaseSP–AfUox cassette** | Does the proposed cassette produce detectable extracellular uricolytic activity in *A. oryzae* before committing to stable integration and scale-up? | Mid wet-lab, ~$500–5000 depending on DNA/vendor and existing fungal transformation workflow | ~2–5 weeks | Proceed to stable strain engineering; modify promoter/signal peptide/linker; test intracellular vs extracellular accumulation; or kill the cassette design | Negative results may reflect transient delivery/copy-number/stress artifacts rather than true cassette failure |

### 1. In-silico secretory-expression liability audit of the α-amylaseSP–AfUox cassette

**Question answered:**  
Whether the designed cassette has obvious computational red flags before any DNA is purchased or assembled.

Recommended analyses at this stage:

- **Signal peptide and cleavage-site prediction** for the α-amylase signal peptide fused to AfUox.  
  - Decision-relevant issue: incorrect cleavage or an unfavorable mature N-terminus can reduce secretion or activity.
- **Fusion-junction review** for steric or charged residues near the predicted signal-peptidase cleavage site.  
  - May inform adding or changing a short linker.
- **Codon-optimization audit** in *A. oryzae*.  
  - Check CAI/tAI, local GC extremes, repeats, homopolymers, strong mRNA secondary structure near the start, unintended restriction sites, and rare-codon clusters.
- **Cryptic eukaryotic processing motifs** in the optimized CDS.  
  - Cryptic splice donor/acceptor motifs, premature polyadenylation-like signals, internal TATA-like elements, upstream ATGs if UTRs are included.
- **Predicted N-/O-glycosylation sites** on AfUox.  
  - Especially those near the active site, tetramerization interface, or substrate channel.
- **Protein-structure sanity check** using known uricase structures and/or AlphaFold/ColabFold-style modeling.  
  - Confirm conservation of catalytic residues and oligomerization interface.
- **Extracellular protease-liability scan** using known fungal protease preferences where available.
- **Subcellular-targeting motif check.**  
  - Native fungal uricases may have intracellular/peroxisomal context; secretion imposes a different folding and trafficking environment.

**Cost:** ~$0 if using public tools.  
**Timeline:** 1–3 days.

**Decision informed:**

- **Proceed** if no major liabilities are detected.
- **Modify specific parameters** if issues are localized:
  - change signal peptide;
  - alter fusion junction/linker;
  - recode local problematic nucleotide regions;
  - remove nonessential predicted glycosylation sites by conservative protein engineering;
  - choose a different uricase ortholog with fewer secretion liabilities.
- **Kill or defer** if multiple independent predictors indicate poor secretion/folding or likely loss of activity upon glycosylation.

**Biggest interpretability risk:**  
Computational predictions can be overinterpreted. They are useful for finding obvious design flaws but are weak predictors of actual fungal secretion yield, proteolytic stability, and post-translational processing.

---

### 2. Parental-strain amyB promoter state-mapping under intended production media

**Question answered:**  
Whether the proposed *amyB* promoter is likely to be active under the intended production process.

This is important because *amyB* is often carbon-source regulated; it should not be assumed to be constitutive. A simple non-GMO assay can map native *amyB* activity in the parent *A. oryzae* strain under candidate media.

Possible readouts:

- endogenous *amyB* transcript abundance by RT-qPCR;
- extracellular α-amylase activity in culture supernatant;
- total secreted protein profile as a secondary context measurement.

Compare conditions relevant to the planned process, for example starch/maltose-rich versus glucose-rich or other carbon sources, without optimizing a full fermentation protocol.

**Cost:** Low wet-lab, typically <$500 if qPCR primers/reagents or amylase assay reagents are available.  
**Timeline:** Several days for an enzyme-activity screen; ~1–2 weeks if including RT-qPCR.

**Decision informed:**

- **Proceed with *amyB*** if it is strongly active under the intended production conditions.
- **Modify process conditions** if *amyB* is active only under specific carbon sources compatible with the production workflow.
- **Modify cassette promoter** if *amyB* is weak, repressed, or too condition-dependent. Candidate alternatives could include commonly used constitutive or process-compatible fungal promoters, selected according to the host strain and regulatory constraints.
- **Kill this cassette architecture** if promoter behavior conflicts with the intended manufacturing constraints.

**Biggest interpretability risk:**  
The endogenous *amyB* locus is not identical to the engineered cassette context. Chromosomal position, copy number, UTRs, terminator choice, and secretory burden can all alter expression. Thus, this assay is most reliable for detecting gross promoter repression, not for predicting final titer.

---

### 3. Small-scale transient secretion-and-activity pilot of the exact α-amylaseSP–AfUox cassette

**Question answered:**  
Whether the actual cassette can produce detectable extracellular uricase activity in *A. oryzae* before committing to stable integration, clone screening, and scale-up.

This is the most biologically direct Phase-0 test. At a small contained scale, transient or episomal expression of the proposed cassette can distinguish several outcomes:

- extracellular uricase activity detectable in supernatant;
- intracellular activity present but little extracellular activity, suggesting secretion/fusion problems;
- no detectable activity despite expression, suggesting folding, processing, glycosylation, or enzyme-inactivation problems;
- no expression signal, suggesting promoter/cassette/delivery issues.

Useful readouts, kept at screening level:

- uric acid depletion assay in supernatant;
- comparison of supernatant versus cell-associated fraction;
- optional immunodetection or activity staining if a validated detection strategy is available;
- inclusion of a secreted positive-control reporter to separate failed delivery from cassette-specific failure.

**Cost:** Mid wet-lab, ~$500–5000. Lower end if the lab already has *A. oryzae* transformation/transient-expression infrastructure and vector backbones; higher end if synthetic DNA and new assay setup are required.  
**Timeline:** ~2–5 weeks, depending mainly on DNA procurement and existing host/vector readiness.

**Decision informed:**

- **Proceed** to stable strain construction if extracellular uricolytic activity is reproducibly detectable.
- **Modify signal peptide or fusion junction** if activity is intracellular but absent from supernatant.
- **Modify promoter** if the cassette appears transcriptionally weak.
- **Modify protein design** if secreted protein is present but inactive, implicating folding, glycosylation, proteolysis, or oligomerization.
- **Kill or replace the cassette** if multiple small-scale attempts with appropriate controls show no activity and no clear single-parameter fix.

**Biggest interpretability risk:**  
Transient expression can give false negatives or misleading positives because delivery efficiency, episomal copy number, stress responses, and non-native expression context may dominate the result. A negative result is especially hard to interpret without an internal secreted-expression control.

---

### Justification for ordering by expected information-per-dollar

1. **In-silico audit first** because it is essentially free and can catch cassette-level design flaws before synthesis or cloning. Even if imperfect, the cost-adjusted value is highest.

2. **amyB promoter state-mapping second** because it is cheap, non-GMO, and addresses a central assumption: that the proposed promoter will be active under production conditions. If *amyB* is repressed in the intended medium, downstream strain construction could fail for a reason unrelated to uricase biology.

3. **Transient secretion-and-activity pilot third** because it is the most directly informative about the full cassette, but it is also more expensive and has more ambiguous failure modes. It is best run after the zero-cost design audit and promoter sanity check have removed obvious avoidable risks.
